AGENDA | JUNE 10 | 12:00 PM EDT
12:00 - 12:10 PM
Welcome & Opening Remarks
Presented By:
Daphne Haim-Langford, PhD, Founder & CEO - Tarsier Pharma
12:10 12:50 PM
Collaborative Case Studies
Moderated By:
Suzana Nahum Zilberberg, Vice Chair - Bio-Light Life Sciences Ltd / Co-Founder - iL.factor
Industry Case Study
12:10 - 12:06 | AEYE Health | Zack Dvey-Aharon, PhD, Co-Founder & CEO
12:06 - 12:12 | Notal Vision | Kester Nahen, CEO
6-minute Fireside Chat (3 questions asked to both parties)
Industry/KOL Case Study
12:20 - 12:26 | Beyeonics Surgical | Ron Schneider, CEO
6-minute Fireside Chat with Anat Loewenstein, MD, Chair, Department of Ophthalmology - Tel Aviv Medical Center / Professor of Ophthalmology, Incumbent of the Sydney A. Fox Chair in Ophthalmology, and Vice Dean of the Faculty of Medicine - Tel Aviv University in Israel
Industry/Investor Case Study
12:32 - 12:38 | EyeYon Medical | Nahum Ferera, CEO & Co-Founder
6-minute Fireside Chat with Michal Geva, Managing Partner & Co-Founder – Triventures
12:50 - 2:15 PM
Company Showcase
12:50 - 12:57 PM | ELGAN Pharma | Miki Olshansky, Co-Founder & CEO
12:57 - 1:04 PM | Orasis Pharmaceuticals | Elad Kedar, CEO
1:11 - 1:18 PM | Blink Energy | Yariv Bar-On, Co-Founder & CEO
1:18 - 1:25 PM | Corneat Vision | Almog Aley-Raz, CEO & VP R&D
1:32 - 1:39 PM | Sanoculis | Nir Israeli, CEO & Co-Founder
1:39 - 1:46 PM | Everads Therapy Ltd | Moshe Weinstein, Executive Chairman & CEO
1:46 - 1:53 PM | Ophthalmic Sciences | Ariel Weinstein, CEO
1:53 - 2:00 PM | Precise Bio | Aryeh Batt, Co-Founder & CEO
2:00 - 2:07 PM | NovaSight | Ran Yam, CEO
2:07 - 2:14 PM | BELKIN Laser | Daria Lemann Blumenthal, CEO
2:15 - 3:05 PM
Industry Insights on Partnering and Collaboration
Panelists:
Begoña Carreño, PhD, Global BD&L Head Ophthalmology - Novartis
Colin Francou, Managing Director - Théa Open Innovation
Yaacov Michlin, CEO - Biolight Life Sciences
Prabhu Velusami, MD, New Venture & Transactions Lead for Vision / Ophthalmology - Johnson & Johnson London Innovation Center
Moderated By:
Robert Rothman, MD, Co-Founder and Managing Member - InFocus Capital Partners / Partner - OCLI/Glaucoma Consultants of Long Island
3:05 - 3:10 PM
Closing Remarks
Presented By:
Suzana Nahum Zilberberg, Vice Chair - Bio-Light Life Sciences Ltd / Co-Founder - iL.factor
3:10 - 4:00 PM
Virtual Networking
PROUDLY SPONSORED BY:
Gold Sponsor
Bausch + Lomb
Bausch + Lomb, a wholly owned subsidiary of Bausch Health Companies, is one of the world's best-known and most respected health care brands, solely focused on protecting, enhancing and restoring people's eyesight.
Silver Sponsors
Alcon
Alcon, the global leader in eye care, provides innovative products that enhance quality of life by helping people worldwide see better. Through Surgical, Pharmaceutical and Vision Care, Alcon offers the world’s widest spectrum of ophthalmic products, helping millions of patients see the world better with clarity, color and beauty.
Promedica International
Promedica International is a privately held, full-service, ISO-certified CRO providing clinical trial services for the medical device, biotechnology and pharmaceutical industries. Founded in 1985, Promedica International, a woman-owned corporation, is headquartered in Orange County, California. We have successfully been providing exceptional value to our clients for over 30 years in clinical trial project management, site recruitment and management, clinical study monitoring, data management, biostatistics, medical writing and GCP auditing.
Bronze Sponsors
Biolight Life Sciences
Biolight Life Sciences Ltd. is a leading company that invests in companies and manages projects in the field of diseases and eye treatments. Biolight's portfolio companies are engaged in advanced medical equipment, drugs, diagnostics and digital medicine and all illustrate the enormous potential of Israeli innovation in these fields.
Orasis Pharmaceuticals
Orasis Pharmaceuticals is an emerging ophthalmic pharmaceutical company focused on developing an innovative eye drop for the treatment of presbyopia symptoms. Promising results from a well powered Phase 2b study have paved an informed path for Orasis to advance their product candidate through successful initiation of Phase 3 studies, NEAR-1 and NEAR-2. Orasis’ differentiated formulation with an optimal balance between efficacy, safety and comfort, along with a proven commercialization strategy in place, positions the company as an emerging leader in the presbyopia space. Follow us on LinkedIn to learn more.
MEDIA PARTNERS:
